Recently announced, Xilinx, Inc. (XLNX) has made a singular achievement with design wins crossing $1 billion in its 28nm field programmable gate array (FPGA) and extensible processing platform (EPP) portfolio.
The Virtex-7 FPGAs are designed to provide the highest bandwidth systems whereas the Kintex-7 FPGAs cater to meeting cost efficiencies and power productivities of the highest standards possible. These 28nm devices shall ameliorate defense radars, video processing systems, medical imaging equipment etc., thereby advancing medical research tools, automotive driver systems, factory automation equipment etc. in days to come.
The Zynq EPP, on the other hand, provides a high performance dual core ARM A9 processor subsystem which shall help reducing power usage and time execution, besides making the products more user-friendly.
By mid-2012, Xilinx hopes to send its entire 28nm product portfolio for sample testing so that it can reap the benefits from seeds sowed as early as possible.
The company recently reported its financial results for its third quarter of fiscal 2012, whereby it recorded a revenue drop of 10% year over year and 8% sequentially to $511.1 million. Operating margin also fell from 32.3% in the year-ago quarter to 26.8% in the last quarter.
However, it is needless to mention that such distinguished advances shall definitely cast an indelible effect on not only the company’s performance in the coming quarters to battle out its formidable competitors like Altera Corp. ((ALTR - Analyst Report)), but also enhance the industry standards considerably.
We maintain our Neutral recommendation on the stock. Our recommendation is supported by Zacks #3 Rank, which translates into a short-term rating of Hold.